Article Sidebar
Published:
Jun 25, 2013DOI:
10.4314/tjpr.v12i3.1Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Development of Transdermal Ondansetron Hydrochloride for the Treatment of Chemotherapy-Induced Nausea and Vomiting
Abstract
Purpose: To to develop and evaluate matrix-type ondansetron hydrochloride (OS) transdermal patch for the treatment of chemotherapy-induced nausea and vomiting.
Methods: Transdermal patches were prepared by solvent casting method using ethyl cellulose and polyvinyl pyrrolidone as matrix materials, and dibutyl phthalate and dibutyl sebacate as plasticizers. The formulations were evaluated for patch thickness, tensile strength, moisture content, water absorption capacity and drug content. In vitro drug release and permeation of the patches were determined using a Franz diffusion cell.
Results: the tensile strength of all the formulations was in the range from 6.09 to 9.85 Mpa indicating that the [patches were strong. Maximum drug release in 8 h for dibutyl phthalate DBP and dibutyl sebacate DBS patches was 38.9 (DB6) and 53.4 % (DS3), respectively, which are significantly (p <
0.01) higher than the lowest values of 17.8 (for DB1) and 35.0 % for (DS5), respectively. Drug release rate was 1.89 and 3.93 ìg/h/cm2, respectively with DS2 and DB2 showing the highest permeation rate
of 5.39 ìg/h/cm2. Patches containing DBP followed Higuchi release model while patches formulated with DBS followed first order release kinetics.
Conclusion: Ondansetron matrix-type transdermal patches formulated with suitable amounts of chemical enhancers for better patient compliance are feasible.
Keywords: Ondansetron hydrochloride, Chemical enhancers, Plasticizers, Dibutyl phthalate, Dibutyl sebacate, Permeation, Patch.
